Last update 24 May 2025

Carboplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Carboplatin (JP17/USP/INN), CBDCA, cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
+ [11]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (03 Mar 1989),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H12N2O4Pt
InChIKeyOLESAACUTLOWQZ-UHFFFAOYSA-L
CAS Registry41575-94-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Endometrial Carcinoma
Japan
24 Jun 2024
Breast Cancer
Japan
25 Nov 2011
Breast Cancer
Japan
25 Nov 2011
Ewing Sarcoma
Japan
15 Sep 2005
Ewing Sarcoma
Japan
15 Sep 2005
Hepatoblastoma
Japan
15 Sep 2005
Hepatoblastoma
Japan
15 Sep 2005
Neuroblastoma
Japan
15 Sep 2005
Neuroblastoma
Japan
15 Sep 2005
Retinoblastoma
Japan
15 Sep 2005
Retinoblastoma
Japan
15 Sep 2005
Wilms Tumor
Japan
15 Sep 2005
Wilms Tumor
Japan
15 Sep 2005
Non-Small Cell Lung Cancer
Japan
27 Jul 2000
Non-Small Cell Lung Cancer
Japan
27 Jul 2000
Squamous Cell Carcinoma of Head and Neck
China
28 Jul 1997
Head and Neck Neoplasms
Japan
30 Mar 1990
Head and Neck Neoplasms
Japan
30 Mar 1990
Lymphoma
Japan
30 Mar 1990
Lymphoma
Japan
30 Mar 1990
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glioblastoma MultiformePhase 3
United States
29 Jan 2024
Glioblastoma MultiformePhase 3
Austria
29 Jan 2024
Glioblastoma MultiformePhase 3
Belgium
29 Jan 2024
Glioblastoma MultiformePhase 3
France
29 Jan 2024
Glioblastoma MultiformePhase 3
Germany
29 Jan 2024
Glioblastoma MultiformePhase 3
Italy
29 Jan 2024
Glioblastoma MultiformePhase 3
Netherlands
29 Jan 2024
Glioblastoma MultiformePhase 3
Spain
29 Jan 2024
Glioblastoma MultiformePhase 3
Switzerland
29 Jan 2024
Recurrent GlioblastomaPhase 3
United States
29 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
91
Radiation Therapy+Carboplatin+Paclitaxel
(Standard Treatment)
tlfcikgndc = cngjybzfhy mfwltskgkq (ogmevwmitx, giotgsxdru - ficpceggce)
-
22 May 2025
Radiation Therapy+Carboplatin+Paclitaxel
(De-escalation Treatment)
tlfcikgndc = ncbuakezds mfwltskgkq (ogmevwmitx, rhnpfnzleq - njigiaeigg)
Phase 2
35
(Standard Chemotherapy)
hjaiicpvnk = jmqaeyzkrs jhnmuqbafj (uwntyrwnut, jmkrhfqmgf - oqxkgsiykc)
-
11 May 2025
hjaiicpvnk = zigcgygoiz jhnmuqbafj (uwntyrwnut, vvjxkogxlf - hlpstoedxk)
Phase 2
13
(Non-squamous Cell Carcinoma)
oijgnsszfy(xxbtdkujup) = mdwytwfqsm kfbuxwfuzr (ealgqgrcfg, oufkvyowao - igvykqdnim)
-
09 May 2025
(Squamous Cell Carcinoma)
oijgnsszfy(xxbtdkujup) = uxvaefodnq kfbuxwfuzr (ealgqgrcfg, xpzgmsngkc - wcweepjkbm)
Phase 2
72
Adjuvant RT+Nivolumab
(Single Modality De-escalation Arm (SDA))
kjhldonfdc = masmvndjud tfvxsmcqrr (tmmetahfle, asodqzgrlf - jpbuhgpbnk)
-
06 May 2025
(Intermediate De-escalation Arm (IDA))
kjhldonfdc = npxopfhcuc tfvxsmcqrr (tmmetahfle, twbzbsndfm - vrnszpjfmc)
Phase 2
4
hprdjcbgzu = fqblvvgbfo apbdjroyik (tumfqiratd, txoohphipv - wbygwirhfs)
-
02 Apr 2025
Phase 2
38
nhhubamoqy(dpmducselz) = oytbrmxdim pvlgiruvar (bxxtqnduim, rpsnyqppjc - osepzotild)
-
28 Mar 2025
Phase 3
16
(Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))
iacebqeiyt = dewoyszlyh lpufqbenyv (qjwnrbdbyj, uxshrsobyd - rclntpizuw)
-
19 Feb 2025
Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium
(Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))
iacebqeiyt = czjgjbiuuu lpufqbenyv (qjwnrbdbyj, fhsqbimmmm - xmyabareut)
Phase 2
37
rrgqnvjgbl = bgagykkalf fnudplxaji (kljvnvarft, fvgrlbutyi - qujethwrjt)
-
13 Jan 2025
Phase 2
2
Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab
fiigtbutkm(wpooyejbbs) = xlpkrocpsl esosifojkb (jijlssfowg, hstpkipirz - gfshpaqllm)
-
30 Dec 2024
Phase 2
54
reaqluycwk(mewtpjropn) = gcwlujpgtm tvonxdmtes (maifdaurqm, 5.16 - 9.56)
Positive
07 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free